Authors [Ref] |
Animal model |
Intervention |
Th1/Th17 |
Details |
Vukkadapu et al., [39] |
BDC2.5/ NOD mice |
- |
↑ IL-17 |
Upregulation of Il17 gene in pancreas and increased IL-17 plasma levels during disease onset. |
Miljkovic et al., [40] |
STZ induced diabetes |
- |
↑ IL-17 |
Increased IL-17 level in diabetic animals, IL-17 promoted upregulation of iNOS and increased beta cell toxicity. |
Mensah-Brown et al., [42] |
STZ induced diabetes |
IL-23 administration |
↑ IFN-γ
↑ IL-17 |
Enhanced diabetogenic process, increased pancreatic inflammation and beta cell loss. |
Jain et al., [43] |
NOD mice |
Ig-GAD2 |
↑ IFN-γ
↓ IL-17 |
Delayed T1D onset at insulitis stage, increased production of IFN-γ and inhibition of IL-17 secretion: reduced islet inflammation, restored normoglycemia at prediabetic stage. |
Emamaullee et al., 2009 [44] |
NOD mice |
Anti-IL-17 antibody or
Recombinant
IL-25 |
↓ IL-17 |
Inhibition of Th17 cells on effector phase: Prevented progression of T1D, reduced islet inflammation and autoantibody formation. IL-25 treatment: restored euglycemia, reduced frequency of Th2 and Th17 cells, increased Treg population. |
Liu et al., [45] |
NOD mice and NOD.Idd3 mice |
- |
↑ IL-17 |
Cells from NOD mice: increased production of IL-21, increased Th17 differentiation, increased production of pro-Th17 mediators by APCs. |
Zhang et al., [46] |
NOD mice |
IL-12 administration |
↑ IFN-γ
↓ IL-17 |
Prevention of T1D development, decreased insulitis, increased healthy islets, decreased Th-17 cytokines levels. |
Spolski et al., [47] |
IL-21 knockout NOD mice |
- |
↓ IL-17 |
Resistance of T1D development, reduced numbers of Th17 cells and IL-17 levels. |
Zhao et al., [49] |
NOD mice |
Bone marrow stromal cells |
↓ IL-17
= IFN-γ |
Decreased blood glucose levels, decreased insulitis, increased Treg cells and decreased Th17 cells. |
Wang et al., [50] |
STZ induced diabetes |
T-cell vaccination |
↓ IFN-γ
↓ IL-17 |
Decreased blood glucose levels, decreased Th1 and Th17 cytokines, increased Th2 cytokines. Transference of Th17 cells accelerated disease development. |
Yaochite et al., [51] |
STZ induced diabetes
(IL-17 receptor deficient mice) |
- |
↓ IL-17 |
Absence of IL-17 signaling: impaired diabetes development, reduced peri-insulits, increased beta cell mass preservation. |
Shi et al., [53] |
NOD mice |
- |
↑ IL-17 |
NOD x Balb/c mice: Decreased Treg cells, increased Th17 cells. Diabetic NOD x Nondiabetic NOD: higher Th17/Treg ratio. |
Bending et al., [56] |
Adoptive transfer system (Th17 cells from BDC2.5 mice to NOD/SCID mice) |
- |
Th17 →Th1 |
Tranfer of Th17 cells induced diabetes in NOD/SCID recipient after conversion into Th1 cells. Neutralizing IFN-γ antibody prevented disease development, anti-IL-17 antibody had no effect. |
Martin-Orozco et al., [57] |
Adoptive transfer system (Th17 cellsin vitro-differentiated from BDC2.5 mice to NOD/SCID mice) |
- |
Th17 →Th1 |
Transfer of Th17 cells induced diabetes in NOD/SCID recipient after conversion into Th1 cells. |
Wan et al., [54] |
Adoptive transfer system (Th17 cells in vitro-differentiated from BDC2.5 mice to NOD/SCID and NOD mice) |
- |
Th17→Th1
(NOD/SCID mice)
Stable Th17 (NOD mice) |
NOD/SCID recipient: Transferred Th17 cells converted into Th1 cells to promote disease.
NOD recipient: Absence of conversion, promoted pancreatic inflammation without clinical diabetes.
|
Van et al., [71] |
Adoptive transfer system (splenocytes from NOD mice to NOD/SCID mice) |
All-trans retinoic acid |
↓ IFN-γ
= IL-17 |
Inhibition of T1D development, decreased islet inflammation, suppression of Th1 but not Th17 cells, Treg expansion. |
Joseph et al., [72] |
IL-17 knockdown NOD mice |
- |
Absence of
IL-17 |
No effect on frequency or disease onset. Dispensable role of IL-17 in T1D pathogenesis. |
Van Belle et al., [55] |
RIP-LCMV mice |
- |
Absence of
IL-17 |
T1D development in absence of detectable IL-17A production. Dispensable role of IL-17A in T1D pathogenesis. |
Ankathatti
Munegowda et al., [52] |
Adoptive transfer system (OVA-specific Th17 cells to RIP-OVA mice) |
- |
- |
Transferred Th17 cells stimulated CD8+ T cells. Activated CD8+ T cells promoted islets destruction via perforin-pathway. Indirect role of Th17 cells in T1D pathogenesis. |
Lau et al., [73] |
Bio-breeding diabetes prone rats (BBDP rats) |
Lactobacilus johnsonii (LjN6.2) |
↑ IL-17 |
LjN6.2 feeding: Diabetes resistance, increased IL-17, IL-23 and IL-6 levels. Protective role of Th17 immune response. |
Nikoopour et al., [77] |
NOD mice |
Mycobacterial adjuvants |
↑ IL-17 |
Prevention of T1D onset, increased levels of IL-17 in spleen, lymph nodes and pancreas. Transference of polarized Th17 cells from CFA-treated NOD mice into NOD/SCID recipient delayed disease onset: important role of IL-17 in this protection. |
Tse et al., [78] |
NAPDH oxidase deficient NOD mice |
- |
↓IFN-γ
↑ IL-17 |
NADPH oxidase deficiency promoted Th17 polarization: protection against T1D and decreased insulitis.
|